The American pharmaceutical company Moderna announced that the United States Food and Drug Administration (FDA) has refused to review the application for authorization for its flu vaccine based on messenger RNA (mRNA) technology, the first of its kind developed by the company, AFP reports. According to Moderna, the decision was communicated in a letter signed by Vinay Prasad, director of the FDA's vaccine regulatory committee. The official motivated the refusal by the fact that the clinical